Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

1653 - Impact of concomitant medications on disease free survival (DFS) and overall survival (OS) in patients from the PETACC8 study.


29 Sep 2019


Poster Display session 2


Tumour Site

Colon and Rectal Cancer


Clémence Brun


Annals of Oncology (2019) 30 (suppl_5): v198-v252. 10.1093/annonc/mdz246


C. Brun1, J. Taieb2, M. Boulin3, K. Le Malicot4, L.M. Dourthe5, B. AVISSE6, P. Laplaige7, C. Borel8, D. Arsene9, F. Kikolski10, B. Denis11, P. Geoffroy12, R. Coriat13, G. Piot14, C. Lepage1

Author affiliations

  • 1 Hepatogastroenterology Department, CHU Dijon, 21079 - Dijon/FR
  • 2 Department Of Gastroenterology And Digestive Oncology, Hopital European George Pompidou, 75015 - Paris/FR
  • 3 Pharmacy Department, CHU Dijon, 21079 - Dijon/FR
  • 4 Biostatistics, FFCD, Dijon/FR
  • 5 Oncology Department, Clinique Sainte Anne, 67000 - Strasbourg/FR
  • 6 Hepatogastroenterology Department, Centre Hospitalier Pierre Oudot, 38302 - Bourgoin-Jallieu/FR
  • 7 Medical Oncology Department, Polyclinique de Blois, 41260 - La Chaussee St. Victor/FR
  • 8 Medical Oncology Department, Centre Paul Strauss Centre de Lutte contre le Cancer, 67065 - Strasbourg/FR
  • 9 Oncology Department, CHU de Caen, 14033 - Caen/FR
  • 10 Gastroenterology And Hepatology, Hôpital Robert Boulin, 33505 - Libourne/FR
  • 11 Hepatogastroenterology Department, Hôpital Louis Pasteur, 68024 - Colmar/FR
  • 12 Hepatogastroenterology Department, Clinique Saint-Vincent, 51200 - Epernay Cedex/FR
  • 13 Gastroenterology Department And Digestive Oncology, Hôpital Cochin, 75014 - Paris/FR
  • 14 Oncology Department, Clinique des Ormeaux, 76600 - Le Havre/FR


Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1653


Impact of comedications and comorbidities upon OS isn’t well described in cancer patients (pts). We aimed to evaluate their impacts on DFS and OS on pts resected from a stage III colon cancer and treated by adjuvant FOLFOX-4 +/- cetuximab in the PETACC8 study.


Treatments (trts) categories were defined according to the WHO ATC classification system. We focused on 4 medication classes: anticoagulant, cardiovascular, antidiarrheal and antidiabetic trts. We classified the 2559 pts in each category if they took trt at baseline or during study whatever the duration was. Kaplan-Meier method and Cox model were used to compare survival curves. Multivariate analyses were performed on the overall population and according to trt arm.


Only 1% of pts had no comedications. Comedications with anticoagulant, cardiovascular, antidiarrheal and antidiabetic trts were observed respectively in 18%, 40%, 30% and 9% of the cases. Patients with antidiabetic or cardiovascular trts had more comorbidities. For each other comedication categories, baseline characteristics were balanced between pts treated or not. All comedication categories, except antidiarrheals, were associated with a significant decrease of DFS and OS (Table). Dose-intensity was balanced and may not explain survival differences. For pts treated with at least one cardiac, diabetic or anticoagulant trts, severe events were more frequently reported, including 9 early deaths. The use of antidiarrheals is maybe associated to a better exposure to chemotherapy as reflected by a higher rate of grade ≥3 adverse events but also a potential better efficacy. Table. Comedications impact on DFS and OS.Table:


Overall analysisDFSOS
HR [95%CI]pHR [95%CI]p
Intake vs no1.33 [1.10–1.62].0031.34 [1.07–1.67].01
Intake vs no0.87 [0.73–1.04].120.78 [0.63–0.96].02
Cardiovascular trts
Intake vs no1.20 [1.03–1.41].021.28 [1.07–1.54].01
Intake vs no1.37 [1.07–1.76].011.45 [1.09–1.92].01


Comorbidities related to analyzed ATC classes negatively impact OS and DFS in PETACC8 pts, except antidiarrheal agents which positively impact OS and DFS.

Clinical trial identification

PETACC8; 2005-003463-23.

Editorial acknowledgement

Legal entity responsible for the study

Fédération Francophone de Cancérologie Digestive, Dijon.


Merck and Sanofi.


J. Taieb: Advisory / Consultancy: Merck; Advisory / Consultancy: Sanofi; Advisory / Consultancy: Roche Genentech; Advisory / Consultancy: Pfizer; Advisory / Consultancy: Amgen. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.